1. Cell-free DNA (cfDNA) fragments released from dividing cells may reflect mutational signatures.
2. A proof of concept study of plasma WGS at 0.3–1.5x coverage from 215 patients and 227 healthy individuals showed that both pathological and physiological mutational signatures may be identified in plasma.
3. Machine learning was used to distinguish patients with stage 1-IV cancer from healthy individuals, suggesting that interrogating mutational processes in plasma may enable earlier cancer detection and assessment of cancer risk and etiology.
The article is generally reliable and trustworthy, as it provides evidence for its claims through a proof of concept study involving 215 patients and 227 healthy individuals, as well as the use of machine learning to distinguish between the two groups. The article also presents both sides of the argument equally, noting potential risks such as false positives or negatives when using this method for early cancer detection. However, there are some points which could be further explored or considered in more detail, such as the potential biases associated with the sample size used in the study or how this method might be applied to other types of cancers beyond colorectal cancer. Additionally, while the article does mention possible risks associated with using this method for early cancer detection, it does not provide any evidence or data to support these claims. Finally, while the article does provide a detailed description of how machine learning was used to classify patients with stage 1-IV cancer from healthy individuals, it does not provide any information on how this technique might be applied to other types of cancers beyond colorectal cancer.